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Abstract
Background: Thyroid cancer is the most common endocrine related cancer with increasing incidences during the past five
years. Current treatments for thyroid cancer, such as surgery or radioactive iodine therapy, often require patients to be on
lifelong thyroid hormone replacement therapy and given the significant recurrence rates of thyroid cancer, new preventive
modalities are needed. The present study investigates the property of a natural dietary compound found in cruciferous
vegetables, 3,39-diindolylmethane (DIM), to target the metastatic phenotype of thyroid cancer cells through a functional
estrogen receptor.
Methodology/Principal Findings: Thyroid cancer cell lines were treated with estrogen and/or DIM and subjected to in vitro
adhesion, migration and invasion assays to investigate the anti-metastatic and anti-estrogenic effects of DIM. We observed
that DIM inhibits estrogen mediated increase in thyroid cell migration, adhesion and invasion, which is also supported by
ER-a downregulation (siRNA) studies. Western blot and zymography analyses provided direct evidence for this DIM
mediated inhibition of E2 enhanced metastasis associated events by virtue of targeting essential proteolytic enzymes,
namely MMP-2 and MMP-9.
Conclusion/Significance: Our data reports for the first time that DIM displays anti-estrogenic like activity by inhibiting
estradiol enhanced thyroid cancer cell proliferation and in vitro metastasis associated events, namely adhesion, migration
and invasion. Most significantly, MMP-2 and MMP-9, which are known to promote and enhance metastasis, were
determined to be targets of DIM. This anti-estrogen like property of DIM may lead to the development of a novel preventive
and/or therapeutic dietary supplement for thyroid cancer patients by targeting progression of the disease.
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Introduction
The incidences of thyroid proliferative diseases (TPD) including
thyroid cancer and goiter, are ever increasing with thyroid cancer
being the most common among endocrine cancers [1,2]. Recent
statistics reveal 37,000 new cases were diagnosed in the US alone
in 2009 and worldwide almost 27 million patients are affected [2].
The well differentiated papillary and follicular thyroid cancers
variants account for more than 90% of all thyroid cancers and are
invasive & metastatic [3]. Current treatments for TPD include
surgery involving complete or partial removal of the thyroid gland,
radioactive iodine (I
131) therapy, chemotherapy or combination of
all [4]. These treatments frequently require patients to take
replacement thyroid hormones throughout life [4,5] with the
recurrence rate being unacceptably high, reaching almost 20–30%
[5,6]. In recent years, the recurrence rate and non-responsiveness
to conventional thyroid treatments has increased thus warranting
investigation of new preventive and therapeutic measures
preferably using natural compounds present in diet.
Diet has always been of prime importance in its association with
cancer development and prevention [7–9]. With respect to cancer
prevention, several studies have found an inverse association of
cancer risk with consumption of dietary products, such as
tomatoes, soy and cruciferous vegetables [7–10]. In particular,
cruciferous vegetables such as broccoli, kale, cauliflower and
cabbage have been accepted by several organizations including the
National Cancer Institute and Federal Drug Administration, to
have a preventive effect against tumor development, especially in
estrogen responsive tissue [7,8]. Cruciferous vegetables contain
several phyto-chemicals including Indole-3-carbinol (I3C), which
is an effective oral chemopreventive agent against breast and
prostate cancers [11–13]. I3C spontaneously converts to its
dimeric product, 3,39-diindolylmethane (DIM) at a low pH
[11–14]. DIM is a stable compound and a safety evaluation
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mice did not lead to any overt renal, cardio or gastro-intestinal
toxicity [15]. This suggests that DIM may be a promising naturally
available bioactive compound which can be used as an anticarc-
inogenic agent as it provides a safer and predictable response.
Currently, the precise cellular and biochemical mechanism by
which DIM exerts its anticarcinogenic effects remains to be fully
elucidated but based on available literature, DIM interferes with
various signal transduction pathways. In breast and prostate
cancers, DIM has been observed to induce dose dependent
apoptosis by inhibiting AKT kinase and IKK-mediated IkBa
phosphorylation, thus leading to inactivation of AKT and
translocation of NFkB to the nucleus, resulting in decreased cell
growth and proliferation [16,17]. Also, it has been reported that
DIM exerts its chemopreventive effects in hormone dependent
cancers such as breast by upregulation of p21
WAFI/CIP1 and the
activation of the JNK pathway [18]. Interestingly, one potential
target of DIM’s activity is estrogen metabolism. Dalessandri et al.
has shown that DIM increased the levels of 2-hydroxyestrones in
postmenopausal women with a history of breast cancer resulting in
an overall increase in 2-hydroxyestrones to 16a-hydroxyestrone
ratio [19] thus favoring anti-proliferative conditions. Smith et al.
have demonstrated that DIM, along with a phytoestrogen,
Genistein can modulate estrogen metabolism towards 2-hydrox-
ylation in estrogen sensitive prostate cancer cells [20]. Recently,
we have also discovered in our laboratory that DIM can modulate
estrogen metabolism in patients with TPD resulting in an increase
in the ratio of 2-hydroxyestrones to 16a-hydroxyestrone (unpub-
lished data) suggesting the use of dietary compounds, such as DIM,
in TPD prevention.
Based on all the information available and discussed in the
literature, this study was designed to define the mechanism(s)
responsible for the anti-cancer effects of DIM in thyroid cancer.
We report that DIM may have therapeutic effects by acting as a
chemo-preventive agent possessing anti-estrogenic properties in
thyroid cells by virtue of downregulating the estrogen induced
cellular phenotypes of adhesion, invasion and migration. Our data
indicates that the anti-estrogen like property of DIM is attributed
to targeting the expression of matrix metalloproteinases (MMPs),
which are essential proteases involved in adhesion, invasion and
migration of cancer cells. Furthermore, the fact that MMPs are
under the transcriptional regulation of the estrogen response




Four thyroid cell lines were used in this study, BCPAP (human
papillary thyroid cancer cell line), 8505C (human papillary thyroid
cancer cell line), CGTHW-1 (human follicular thyroid cancer cell
line) and ML-1 (human follicular thyroid cancer). BCPAP, 8505C
and CGTHW-1 were cultured in RPMI-1640 (Mediatech,
Herndon, VA) supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals, Atlanta, GA), penicillin 10,000 IU/ml,
streptomycin 10,000 mg/ml (Mediatech) and 2 mM L-glutamine
(Mediatech) ML-1 was grown in DMEM (Mediatech) supple-
mented with 10% FBS, penicillin 10,000 IU/ml, streptomycin
10,000 mg/ml and 2 mM L-glutamine. BCPAP, 8505C,
CGTHW-1 and ML-1 cell lines were purchased from DSMZ,
Braunschweig, Germany. MCF-7 (human breast cancer cell line)
was obtained from American Type Culture Collection (ATCC)
(Manassas, VA) and grown in DMEM supplemented with 10%
FBS, penicillin, streptomycin, insulin and L-glutamine.
Western Blot analysis
Cells were harvested using 0.25% trypsin (Mediatech), washed
with PBS, and lysed (1610
6/100 mL of lysis buffer) using the
radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 0.2% sodium deoxycholate, 0.1% SDS,
0.5% NP40, 1 mM Pefabloc] and incubated on ice for 30 minutes
with intermittent vortexing. The lysates were centrifuged at
14,000 rpm for 30 min at 4uC and supernatant were collected.
Cell lysates (20 mg protein) were subjected to 12% SDS–PAGE
under reducing conditions (presence of b-mercaptoethanol) as
described earlier [21,22]. Briefly, the proteins were transferred to
Immobilon-P membranes at 220 mA for 2 h and membranes were
blocked with 4% dried milk in TBST [200 mM Tris–HCl,
pH 7.4, 150 mM NaCl, and 0.01% Tween-20 added fresh/liter of
16 TBS (TBST)] for at least 2–3 h on a shaker at room
temperature. Subsequently, the membranes were incubated
overnight at 4uC with either ER-a (Abcam, Cambridge, MA),
ER-b (Santa Cruz Biotechnology, Santa Cruz, CA) antibody or
actin (Santa Cruz Biotechnology) in TBST. Membranes were
washed three times with TBST and incubated with the respective
horseradish peroxidase (HRP) conjugated secondary antibody, for
2 hours at room temperature in TBST containing 2% milk. After
four washes with TBS-T and one wash with TBS, membranes
were developed by ECL substrate (Pierce Rockford, IL) and
detected on Denville autoradiography films.
XTT cell proliferation assay
Two thousand cells in 200 ml medium were plated into each
well of 96-well plates and incubated overnight to allow cell
adherence. The media was removed and 3,39-diindolylmethane
(DIM), kindly provided by Dr. Michael Zeligs (BioResponse,
Boulder, Colorado) was added at concentrations of either 10, 25,
50, 75, 100, or 500 mM in a total volume of 200 ml and incubated
for 24 h. The media were discarded and fresh growth media were
added without DIM followed by addition of 50 ml XTT [1 mg/ml
in serum-free RPMI + phenazine methosulfate (25 nM)]. After
4 hours of incubation, the OD was taken in a microplate reader at
450 nm and reference at 630 nm. The mean OD values were
calculated for each dose at the respective time points and the
percent survival as a function of time and dose was used to
compare the experimental and control groups.
Clonogenic Assay
To determine the effect of DIM on the clonogenicity, BCPAP,
8505C, CGTHW-1 and ML-1 cells were plated in six-well plates
(200 cells per well). The cells were allowed to adhere overnight
after which fresh media containing 610
28 ME 2 650 mM DIM
was added or left untreated. After 21 days in culture, the cells were
fixed and stained using 0.025% Coomassie brilliant blue R250 (in
50% methanol and 10% acetic acid) to visualize cell colonies. The
colonies were counted, and percentage inhibition of clonogenicity
was determined in the treated cells.
Transwell Migration Assay
BD Biocoat Control Inserts (BD Biosciences, Bedford, MA) with
8-mm pore membrane filters were used for the migration assay as
previously described [21,23]. Briefly, cells were starved for
18 hours using starvation medium [phenol red-free medium
supplemented with 10% charcoal stripped FBS (Sigma Chemical
Co.) and penicillin (10,000 IU/ml)]. Cells were then harvested by
trypsinization and 2.5610
4 cells were seeded in the upper
chamber in 500 ml of media containing 1% FBS 610
28 ME 2
610
26 M fulvestrant 625 mM DIM. The lower chamber
3,39-Diindolylmethane (DIM) and Thyroid Cancer
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18 hours of incubation, the non migrating cells were removed
from the upper surface of the membrane by gently scrubbing using
cotton tipped swab. Cells on the lower surface of the membrane
were then fixed using methanol and stained using 1% toluidine
blue 1% borax stain followed by two washes with distilled water.
Inserts were then allowed to airdry and counted in 10X field. Data
are expressed as numbers of migrated cells per 10X field
micrograph for each sample well and normalized to cell counts
obtained from the untreated control.
Scratch Wound Assay
Migratory ability of BCPAP, 8505C, CGTHW-1 and ML-1
cells was also assessed by a scratch wound assay. 5610
5 cells were
plated in a six well plate and allowed to adhere and grow to 60–
70% confluent cell monolayers. Subsequently, three vertical
wounds were caused per well using a 2.5 ml sterile pipette tip
followed by removal of any cellular debris and detached cells. The
wounded cell monolayer was then incubated in fresh complete
media with or without 25 and 50 mM DIM and estradiol. One
horizontal line was made to allow visualization of cells at the same
point. The cells were inspected every three hours until the scratch
cells for control were fully migrated from one end of wound to
other, which was 24 hours for BCPAP, 8505C and CGTHW-1
and 48 hours for ML-1. Pictures were taken just above and below
the horizontal mark using a light microscope at 5X.
Cell Adhesion assay
BCPAP, 8505C, CGTHW-1 and ML-1 cells were harvested as
described and seeded at a density of 5610
5 cells per well in 6-well
culture dishes in media supplemented with 610
28M E 2
610
26 M fulvestrant 625 mM DIM or left untreated and allowed
to adhere for 2 hours. After indicated time points, medium with
non-adhered cells was discarded and wells were gently washed
twice with PBS to remove any loosely attached cells. Adherent
cells were then scraped and counted using 0.4% trypan blue
solution (Sigma Chemical Co., St. Louis, MO). The numbers of
adherent cells were counted using a hemocytometer and the effect
of DIM on cell adhesion was expressed as percent decrease in
adherent cell count for cells treated with DIM relative to control
cells.
Invasion assay
Invasion assay was performed as previously described [21] using
BD Biocoat growth Factor Reduced Matrigel Invasion chambers
(BD Biosciences, Bedford, MA) with 8-mm pore membrane filters
which were coated with matrigel. The protocol was essentially the
same as migration assay except that growth factor reduced
matrigel invasion chambers were rehydrated for 2 hours using
serum free RPMI media at 37uC prior to loading cells onto inserts.
Once rehydrated, 2.5610
4 cells were resuspended in the RPMI
(500 ml) containing 1% FBS with 610
28 ME 2 610
26 M
fulvestrant 625 mM DIM and were carefully transferred onto
the upper surface of filters in the chamber. Cells were allowed to
invade for 18 hours after which cells were stained and counted
similarly as described for migration assay. Percent invasion was
calculated based on the percent of cells invading through the
growth factor reduced matrigel invasion chambers relative to the
cells migrating through control membrane.
MMP detection
Thyroid cells were seeded at a density of 5610
5 cells per well in
6-well culture dishes and allowed to adhere overnight after which
they were then switched to serum free medium and incubated with
610
28 ME 2 610
26 M fulvestrant 625 mM DIM or left
untreated for 24 hours. Conditioned medium was harvested,
centrifuged to remove any debris, and aliquots were stored at
280uC until analyzed for MMP-2 and MMP-9 secretion and
activity as described earlier [24,25]. Briefly, the total protein
concentration of the conditioned medium was determined using
the Bio-Rad protein assay dye and equal proteins were used for
each experiment. For gelatin zymography, SDS-PAGE gels were
copolymerized with 0.1% gelatin (Sigma Chemical Co.) and 1 mg
protein was resolved under non-reducing conditions. Following
electrophoresis, gels were washed twice in renaturation buffer
(2.5% Triton X-100 in distilled water) for 1 h on an orbital shaker.
The zymograms were incubated for 1 h at room temperature
followed by 36 hours at 37uC in zymography buffer (5 mM CaCl2,
0.2 mM NaN3 and 1 mM ZnCl2 in 50 mM Tris–HCl) with buffer
changes every 12 hours. Gels were then stained with Coomassie
blue (G-250 stain, Bio-rad Laboratories, Hercules, CA) and
destained with 10% methanol and 7.5% acetic acid. Western blot
analysis was performed using conditioned medium from thyroid
cancer cells (equal protein concentrations) as described in the
previous section using MMP-2 and MMP-9 (Cell Signaling
Technology Inc., Danvers, MA) antibodies. For MMP inhibition,
general MMP inhibitor 1,10 phenanthroline (Sigma Chemical
Co.) was used. 2.5610
4 cells were resuspended in the RPMI
(500 ml) containing 1% FBS with 610
28 ME 2 620 mM 1,10
phenanthroline 625 mM DIM and seeded on BD Biocoat Control
Inserts for migration and matrigel coated inserts for invasion as
described in previous sections.
siRNA and transfection conditions
For silencing estrogen receptor studies, ER-a small interfering
RNA (siRNA) and siRNA transfection reagent (DharmaFECT1)
were obtained from Dharmacon (Dharmacon, Inc., Lafayette,
CO). BCPAP and MCF-7 cells were plated in 6 well plates and
allowed to adhere overnight. Cells were transfected for 48 hours,
and subsequently trasfected cells were harvested and seeded on BD
Biocoat Control Inserts (migration) and matrigel coated inserts
(invasion) in media containing 1% FBS 610
28 ME 2 610
26 M
fulvestrant 625 mM DIM. Non-transfected thyroid cancer cells
treated with 610
28 ME 2 610
26 M fulvestrant 625 mM DIM
were used as appropriate positive controls. The migration and
invasion studies were performed as described in previous sections.
Statistical Calculation
Experiments presented here represent three replicates with
statistical significance determined using a paired Student’s t test
with a probability (‘p’ value) #0.05 used to reject the null
hypothesis.
Results
Thyroid cells express estrogen receptor
The thyroid is not known to act as a traditional estrogen
responsive tissue such as breast. In order to determine the status of
the estrogen receptor in thyroid cells, we used four thyroid cell
lines as our cell culture models. BCPAP and 8505C are human
papillary thyroid cancer cell lines, CGTHW-1 and ML-1 are
human follicular thyroid cancer cell lines. We observed that all the
thyroid cell lines assayed expressed both isoforms of estrogen
receptor (ER), ER-a and ER-b (Fig. 1) at comparable levels. MCF-
7, a classical ER expressing breast cancer cell line, was used as a
positive control for detection of both polymorphic forms of ERs
(ER-a and ER-b).
3,39-Diindolylmethane (DIM) and Thyroid Cancer
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DIM, a natural compound from cruciferous vegetables has been
observed to have anti-proliferative properties against several
hormone responsive cancers [14,16–18]. We wanted to evaluate
the effect of DIM on the proliferative activity of thyroid cancer
and in order to do so, an XTT assay was performed and the results
are shown in Table 1. All the cell lines (BCPAP, 8505C,
CGTHW-1 and ML-1) used in this study were treated with
various concentrations of DIM for 24 hours. A dose dependent
inhibition in cell viability was observed with a 50% inhibition at a
concentration of approximately 50 mM DIM during 24 h of
treatment in all four cell lines, BCPAP, 8505C, CGTHW-1 and
ML-1. Based on these observations (Table 1), the 25 mM DIM
concentration was used to further characterize the effects of DIM
on thyroid cells at both the molecular and phenotypic levels.
DIM inhibits the clonogenic ability of thyroid cells
One of the hallmark properties of cancer cells is the ability to
divide under isolated conditions using minimal paracrine and
possibly more autocrine factors [26]. The anticancer effect of DIM
on the ability of BCPAP, 8505C, CGTHW-1 and ML-1 cells to
divide indefinitely was evaluated by a clonogenic cell survival
assay. Two hundred cells per well in six well plates were treated
with 50 mM DIM 6 estradiol for 21 days. As shown in Table 2,
the untreated thyroid cells have the ability to form clones whereas
estrogen treatment resulted in approximately 8 (8505C) 233%
(ML-1) increase in clone formation depending on cell lines. DIM
completely abrogated clone formation of all cell lines irrespective
of whether they were treated with estradiol. These experiments
establish the differential responsiveness of different thyroid cancer
cells to estradiol and the anti-estrogenic activity of DIM.
DIM reduces the migratory ability of thyroid cells
Tumor cells have an enhanced ability to migrate into
neighboring tissue and certain agents such as estradiol have been
observed to aid in this migration process. Therapeutic agents
which can lower the ability of these cells to migrate can
presumably effectively lower the risk of metastasis. We have
previously demonstrated that thyroid cells have the ability to
increase migration in response to estrogen [21] and to determine if
DIM can affect the migratory potential of these cells, in vitro
migration assays were performed. Starved thyroid cells were
seeded in a transwell migration chamber with estradiol 6
fulvestrant or 625 mM DIM and allowed to migrate. We observed
that thyroid cells were capable of migrating and this ability to
migrate was enhanced when cells were treated with E2 (grey bars)
compared to untreated cells with 30% increase in migration for
BCPAP, 50% for 8505C, 89% for CGTHW-1 and 63% for ML-1
(Fig. 2A). This increase in cell migration was abrogated when
fulvestrant was used along with estradiol [dotted bars) suggesting
that the migratory ability of these thyroid cells is influenced by
estrogen and an estrogen receptor antagonist has abrogated the
migration of these cells. DIM (25 mM) significantly decreased
migration of thyroid cells (black bars). This decrease was observed
to be approximately 37–57% and was cell line dependent.
Moreover, the addition of estradiol along with 25 mM DIM
(striped bars) did not improve the migratory ability of thyroid cells,
signifying the antiestrogen like ability of DIM.
To further validate the effect of DIM on the migratory
capability of thyroid cells, a scratch wound assay was performed,
which is a partial in vivo representation of metastatic phenotype
[27]. Thyroid cells (BCPAP, 8505C, CGTHW-1 and ML-1) were
grown in a 60–70% confluent monolayer followed by formation of
scratches and subsequent incubation with 6 DIM. We found that
the DIM caused a decrease in cell migration by 50–60% (as
observed visually) in a dose dependent manner in thyroid cells
[BCPAP (Fig. 2B) and CGTHW-1 (Fig. 2C)]. Similar results were
observed with 8505C and ML-1 (data not shown). We have also
previously observed that estradiol enhances migration and this
migration was inhibited by fulvestrant, similar to the scratch
wound assay results obtained in this study using DIM [21].
Figure 1. Thyroid cells express estrogen receptor. Whole cell
protein (20 mg) was resolved by SDS-PAGE followed by Western blot
analysis for ER-a (dilution 1:500), ER-b (dilution 1:1000) and actin
(dilution 1:5000). All the cell lines used in this study (BCPAP, 8505C,
CGTHW-1 and ML-1) express both ER-a and ER-b at comparable levels.
doi:10.1371/journal.pone.0015879.g001
Table 1. Thyroid cell survival assay.
DIM
concentration
(mM) BCPAP 8505C CGTHW-1 ML-1 MCF-7
untreated 100601 0 0 60 100601 0 0 601 0 0 60
10 91.969 98.162.9 95.164.2 90.860.9 86.460.1
25 87.967.5 88.960.8 85.867.4 77.765.6 62.660.3
50 43.864.3 49.065.4 46.464.4 54.263.9 46.562.6
100 18.668.9 28.863.4 14.562.9 31.664.6 23.464.8
500 1.1960.6 21.967.2 4.1462.5 19.163.7 21.260.9
The numbers above represent the percent of viable cells with various
concentrations of DIM. The percent survival was calculated based on untreated
cells which were set as 100%.
doi:10.1371/journal.pone.0015879.t001
Table 2. DIM inhibits clonogenicity of thyroid cells.
Treatments BCPAP 8505C CGTHW-1 ML-1 MCF-7
untreated 10060 10060 100601 0 0 601 0 0 60
10
28 ME 2 10962.3 108.1610.7 122.564.3 133.361.4 154.768.7
50 mM DIM 0 0 0 0 0
10
28 ME 2
+50 mMD I M
00 0 00
Thyroid cell were cultured under various conditions for 21 days. The numbers
above are in % clone and were calculated based on untreated cells which were
set as 100%.
doi:10.1371/journal.pone.0015879.t002
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In order to successfully metastasize, tumor cells have to adhere
to the extra cellular matrix (ECM) of secondary organs [26,28].
We evaluated the effect of DIM on adhesion of thyroid cells by
performing an adhesion assay. Thyroid cells were allowed to
adhere in the presence of 10
28 ME 2 or 610
26 M fulvestrant (a
classical estrogen receptor antagonist) 625 mM DIM for 2 hours
and % adhesion was calculated (Fig. 3). An increase in adhesion
was observed when cells were treated with E2 (grey bars), which
was abrogated with fulvestrant (dotted bars) suggesting that
adhesion is an active phenotype in thyroid cells possibly requiring
functional ER activity. Interestingly, a significant decrease in
adhesion was observed when cells were treated with 25 mM DIM
(black bars), with a 58% decrease in adhesion for BCPAP, 42% for
8505C, 70% for CGTHW-1 and 45% for ML-1. Combination of
estradiol and 25 mM DIM (striped bars) could not improve the
adhesion of thyroid cells, suggesting that DIM may prevent
estrogen enhanced adhesion and can potentially act as an effective
anti-estrogen/metastatic agent, as the decrease in cell adhesion by
DIM is similar to the decrease in adhesion observed with the
estrogen receptor antagonist fulvestrant.
DIM inhibits the invasion of thyroid cells
Formation of secondary metastatic foci by tumor cells requires
invading the ECM of secondary organs [26] and inhibiting this
invasion is a strategy in cancer therapy that has been widely
investigated. The effect of DIM on the invasive potential of
BCPAP, 8505C, CGTHW-1 and ML-1 was assayed through the
use of a transwell invasion chamber coated with a biological
matrix in vitro (matrigel). Thyroid cells were loaded in a transwell
chamber with estradiol 6 fulvestrant or 625 mM DIM and were
allowed to invade through the matrigel. We observed that thyroid
cells were capable of invading through matrigel and invasion by
these cells was enhanced when cells were treated with E2 (grey
bars) with an 40% increase in invasion for BCPAP, 36% for
8505C, 30% for CGTHW-1 and 31% for ML-1 (Fig. 4). This
increase in cell invasion was abrogated when fulvestrant was used
in combination with estradiol (dotted bars) suggesting that an
estrogen receptor antagonist can block the invasive propensity of
thyroid cells. To evaluate the effect of DIM on invasion of thyroid
cells, all the cell lines were treated with 25 mM DIM (black bars)
and a significant decrease (p,0.05) in invasion was observed. This
decrease in invasion was approximately 52% for BCPAP, 50% for
Figure 2. DIM reduces migration of thyroid cells. (A) 2.5610
4 cells were resuspended in 500 ml of RPMI with 1% FBS 610
28 ME 2 610
26 M
fulvestrant 625 mM DIM and seeded in the upper chamber of BD Biocoat Control Inserts (8-mm pore membrane filters). 750 ml of RPMI containing 5%
FBS was added to the bottom chamber as a chemoattractant. After 18 hours, the cells that migrated were fixed, stained, and counted under the 10X
objective. The groups are as follows- untreated (white bars), E2 treated (grey bars), E2 + fulvestrant (dotted bars), 25 mM DIM (black bars) and E2
+25 mM DIM treated (striped bars). Data is expressed as numbers of cells counted (migrated cells) for each sample and normalized to the cell number
obtained from the untreated control. The asterisk denotes statistically significant differences (p,0.05) between the indicated samples. Scratch wound
assay for BCPAP (B) and CGTHW-1 (C). 5610
5 cells were plated and allowed to grow to semi confluent monolayers after which a ‘vertical wound’ was
created and cells were then allowed to migrate in the presence of either 25 mMo r5 0mM DIM. The cells were visualized under 5X every three hours
and photographic documentation was taken at 18 hours when the cells completely migrated from one end of ‘scratch’ to other end in untreated
controls.
doi:10.1371/journal.pone.0015879.g002
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to control cells (normalized to 100% and p,0.05). Furthermore,
pro-proliferative estradiol, in combination with DIM (striped bars),
did not improve the invasive ability of thyroid cells. This data
suggests that DIM abrogates estrogen enhanced cellular processes
of invasion thus possibly targeting a major step in tumor
progression and metastasis.
DIM suppresses estrogen induced MMP secretion
MMPs are reliable markers of tumor cell invasion and
migration. Moreover, malignant tumors are known to have
increased MMP expressions compared to benign tumors, which
causes degradation of the extracellular matrix, resulting in
increased invasion and migration of tumor cells [29,30].
Phytochemicals such as genistein and I3C have been shown to
target the activity and secretion of MMPs in estrogen responsive
cancers [31]. Thus, to determine if estrogen and/or DIM, a
phytochemical, could modulate MMP-2 and MMP-9 secretion
and activity in thyroid cancer cells, we stimulated BCPAP and
ML-1 cells with estrogen 625 mM DIM or 6 fulvestrant and
measured MMP-2 and MMP-9 protein secretion and activity by
performing Western blot analysis and zymography, respectively
using conditioned medium from thyroid cancer cells. As seen in
Fig 5, estrogen treatment resulted in an increased MMP-2 and
MMP-9 protein secretion (5A & 5B) and activity (5C) compared to
untreated controls. The levels of MMP secretion and activity were
downregulated when thyroid cells were treated with 25 mM DIM.
DIM was also able to suppress the estrogen induced enhanced
secretion of MMP-2 as well as MMP-9 suggestive of its anti-
estrogen like ability. To further evaluate the role of MMPs in
thyroid cell invasion and migration, a general MMP inhibitor,
1,10 phenanthroline was used. 1,10 phenanthroline was able to
significantly attenuate the migration and invasion of thyroid cells.
Even when cell were subjected to 1,10 phenanthroline and
estrogen (Fig. 6) together, the pro-migratory and invasive abilities
of estrogen were nullified. More interestingly, when DIM and 1,10
phenanthroline were added together, only 9–11% of cells were
able to migrate and 19–20% of cells invaded, suggesting a
definitive role of these enzymes in the migration and invasion of
thyroid cancer cells.
ERa silencing attenuates DIM induced inhibition of
Migration and Invasion
Activation and secretion of MMP by estrogen is known to be
ER dependent and this stimulation can lead to enhanced
migration and invasion of tumor cells, thus, we used ER silencing
to further elucidate the mechanism of action of estrogen and DIM
on the migration and invasion of thyroid cells. The efficiency of
ER silencing in BCPAP cells was determined by Western Blot
analysis in which a decreased expression of ER was observed
(Fig 7A). Migration and invasion were observed in untreated
transfected cells suggesting that the process of transfection did not
alter any cellular phenotype pertaining to the migratory and
invasive properties of BCPAP. Loss of the estrogen receptor by
siRNA tranfection resulted in loss of estradiol mediated migration
and invasion of thyroid cancer cells with the activity of DIM also
nullified (Fig 7B & 6C). The E2 stimulation on migration and
invasion was minimal with 13% on migration and 23% on
invasion for B-CPAP and the addition of DIM did not affect
migration and invasion as the results were comparable to the
control (Fig 7). As a further positive control for our ER silencing
experiments, the human estrogen responsive breast cancer cell
line, MCF-7, was used. The effectiveness of ER silencing for MCF-
7 was also determined through Western Blot (Fig. 7A) and the
migration and invasion results observed with MCF-7 (Fig 7B &
Figure 3. DIM decreases adhesion of thyroid cells. 5610
5 cells were suspended in complete medium containing 610
28 ME 2 610
26 M
fulvestrant 625 mM DIM and plated in 6 well culture dishes. After 2 hours viable adhered cells were removed by scraping and counted by trypan
blue. The groups are as follows- untreated (white bars), E2 treated (grey bars), E2 + fulvestrant (dotted bars), 25 mM DIM (black bars), and E2 +25 mM
DIM treated (striped bars). Data are expressed as % adhered cells compared to untreated cells which were set to 100% adhesion. Single asterisk
denotes statistically significant differences (p,0.05) between the indicated samples.
doi:10.1371/journal.pone.0015879.g003
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essential function of estradiol in thyroid cancer cell metastasis and
the target of DIM as being anti-estrogenic. These results were
similar when the ER antagonist fulvestrant was added in the E2
stimulated transfected cells, further suggesting that the E2-ER
signaling has significance in migration/invasion upon estrogen
stimulation.
Discussion
Thyroid cancer, the most prevalent endocrine-based cancer,
occurs four to five times higher in women than in men suggestive
of the possible involvement of estrogen in its development. We
have recently demonstrated that thyroid cells are estrogen
responsive and estrogen can not only modulate thyroid cancer
cell proliferation but also metastasis associated events [21].
Estrogen mediated changes at the cellular level are mostly
mediated via its receptors, ER-a and ER-b, which influence
several pro-survival pathways [32,33]. Estrogen is known to
influence cell proliferation by inducing transcription of several
genes such as c-jun, c-myc and c-fos, as well as growth factors,
such as TGF-a and EGF and also directly influences cyclins that
regulate the cell cycle [34]. Furthermore, the binding of estrogen
to either membrane bound and/or cytosolic estrogen receptor
results in activation of several intracellular signaling pathways,
such as the PI3K/Akt and ERK pathways, which upon activation
lead to anti-apoptotic signals [32–35]. Many reports indicate that
these E2-ER mediated signals can subsequently result in
development of the metastatic phenotype, characterized by
increased cell proliferation, migration and invasion of several
cancers, in particular, breast cancer [36–38]. The link between
estrogen and thyroid cancer opens up the possibility of using anti-
estrogens for thyroid cancer treatment.
Several anti-estrogenic synthetic compounds exist, such as
tamoxifen and ICI 182,780 (fulvestrant), which prevent activation
of the Akt and ERK pathways by virtue of their competition with
E2 for binding to the ER [39]. Unfortunately, the use of these
antiestrogens have undesirable side effects such as ICI 182,780
resulting in a complete blockade of activation pathways of ER and
tamoxifen resulting in detrimental uterotrophic effects and can act
as agonist for breast cancer cell growth [39,40]. Overall, these
damaging effects warrant the research for safer alternatives to
synthetic antiestrogens. Interestingly, one way to possibly treat
thyroid cancer is through the use of natural dietary compounds
such as DIM, provided that DIM has been shown to effect
estrogen responsive tissues such as breast.
DIM is a natural compound that is found in cruciferous
vegetables and has widely been investigated for its anti-
carcinogenic effects against several types of cancers such as breast
and prostate [16,17]. Although the exact mechanism of DIM’s
anti-carcinogenic property needs further investigation, several
studies seem to concur that the downstream effects of DIM are to
target essential events involved in cancer cell proliferation and
metastasis. Our group has also observed these anti-proliferative
actions of DIM but we are also ascribing a potentially new
function to DIM, which is acting as an anti-estrogen by possibly
targeting both genomic and non-genomic E2-ER signaling
pathways. In this study, we observed that DIM acts in a similar
fashion to the anti-estrogenic compound fulvesterant by inhibiting
estrogen induced proliferation and clone formation of thyroid
cancer cells. DIM was also observed to interfere with essential
events involved in cancer cell metastasis as evidenced by a
decrease in in vitro cell adhesion, migration, and invasion. Of these
three crucial steps involved in initiating metastasis, invasion is the
most essential one. An agent that could efficiently inhibit the
ability of cancer cells to form secondary metastatic foci would be
an ideal candidate to suppress cancer progression. We observed
that DIM has a unique anti-invasive property, with as high as 78%
inhibition of invasion observed in papillary thyroid cancer cells.
Most importantly, we observed that estradiol mediated migration
Figure 4. DIM reduces invasion of thyroid cells. 2.5610
4 cells resuspended in 500 ml medium containing 1% FBS 610
28 ME 2610
26 M
fulvestrant 625 mM DIM were seeded in the upper chamber of growth factor reduced matrigel invasion chambers. 750 ml of growth medium
containing 5% FBS was used as chemoattractant in the bottom chamber. Percent invasion was calculated based on the number of cells invading
through the chambers relative to the cells migrating through control membrane after 18 hours. The groups are as follows- untreated (white bars), E2
treated (grey bars), E2 and ICI (dotted bars), 25 mM DIM (black bars) and E2 &2 5mM DIM treated (striped bars). Data is represented as % invasion
which is mean number of invaded cells per 10X field micrograph for each sample well relative to the migration through the control membrane and
normalized to the untreated control. The asterisk denotes statistically significant differences (p,0.05) between the indicated samples.
doi:10.1371/journal.pone.0015879.g004
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medium from thyroid cells treated with 10
28 ME 2610
26 M fulvestrant 625 mM DIM for 24 hours were collected and total protein concentration was
determined. One microgram (mg) of protein for each treatment was resolved by SDS-PAGE followed by Western blot analysis for MMP-2 (dilution
1:1000) (A), MMP-9 (dilution 1:1000) (B) and zymography (C). In zymography, areas of MMP enzymatic activity appeared as clear bands over the dark
blue background. Shown are densitometric values with untreated samples set as 100% and average of three independent experiments.
doi:10.1371/journal.pone.0015879.g005
Figure 6. MMP inhibitor 1,10 phenanthroline attenuates migration and invasion of thyroid cells. Thyroid cells were treated with 10
28 M
E2 6 MMP inhibitor (1,10 Ph) 625 mM DIM or left untreated and percent migration and invasion of treated cells was determined compared to
untreated cells which were set to 100%.
doi:10.1371/journal.pone.0015879.g006
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when DIM and estrogen were added together in cell cultures.
Tumor cell invasion is facilitated by proteolytic enzymes which
degrade the extracellular matrix (ECM) of the surrounding tissue
leading to the formation of secondary foci. Two such proteolytic
enzymes are MMP-2 and MMP-9, which belong to a large family
of zinc dependent endopeptidases involved in degradation of ECM
proteins. MMPs are secreted by cells as proenzymes which become
catalytically active by either autoactivation or by other proteinases.
The ECM is not only a solid state support for cells, but it also
serves as a reservoir for various essential bioactive molecules such
as cytokines and growth factors which are released by MMP
induced degradation [41] thus providing a depot of bioactive
molecules that aid in tumor cell metastasis and angiogenesis.
Interestingly, growth factors are demonstrated to stimulate MMP-
9 activation in head and neck squamous cell carcinoma [42] and
elevated levels of MMPs have been demonstrated in thyroid
carcinoma. Yeh et. al demonstrated that MMPs are critical
effectors of invasion in papillary and follicular thyroid cancer cell
lines [43]. In addition, estrogen has been shown to regulate the
activity of MMP-2 and MMP-9 in ER+ breast cancer cells [44]
and a positive correlation between ER-a expression and the effects
of estrogen on MMP gene expression in breast cancer cells [45]. In
this study, we observed that MMP-2 and MMP-9 secretion was
increased with estrogen treatment of ER+ thyroid cancer cells,
which was suppressed by treatment with DIM, providing not only
a correlative link but a direct validation of the anti-estrogenic
activity of DIM that alters thyroid cancer cell phenotype.
Therefore, our observations along with the aforementioned studies
[44,45] provide a strong correlative link between E2-ER signaling
and MMP secretion. In addition, it is known from recent reports
that the interactions between the cancer cells and stromal cells
may enhance the growth and progression of tumor [46]. The exact
mechanism by which DIM and/or estrogen are affecting the
tumor microenvironment need to be further elucidated.
Lastly, recent publications which implicate the involvement of
estrogen with increased metastatic phenotypic properties coupled
with an observation in which DIM inhibits these estrogen
mediated metastasis associated events (current study), prompted
us to validate our observations by ER-knockdown studies using
BCPAP. Silencing of the ER was able to abrogate the pronounced
DIM mediated inhibition of E2 induced cell migration/invasion in
normal non-transfected cells. This observed phenomenon was
comparable to the ER silenced MCF-7 cell line thus authenticat-
ing the presumed antiestrogenic activity of DIM which appears to
utilize the estrogen receptor and its ability to modulate E2-ER
Figure 7. ER-a silencing inhibits DIM’s effect on migration/invasion. (A) Western Blot analysis demonstrating downregulation of ER-a. BCPAP
and MCF-7 cells were transfected with siRNA and whole cell protein was resolved by SDS-PAGE followed by Western blot analysis for ER-a. A decrease
in ER-a expression was observed for both BCPAP and MCF-7 confirming ER-a silencing. Actin was used as a loading control. (B & C) Cancer cells were
transfected with ER-a siRNA and subsequently treated with 10
28 ME 2610
26 M fulvestrant 625 mM DIM or left untreated. Data presented
demonstrates percent migration (B) and invasion (C) of ER-a silenced cancer cells treated with E26 fulvestrant 6 DIM compared to untreated ER-a
silenced cancer cells which were set to 100%. MCF-7 was used as positive control for ER silencing experiments.
doi:10.1371/journal.pone.0015879.g007
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such as the pAkt and ERK pathways, as described earlier by us
and others [14,47–50].
Collectively, our observations provide evidence that DIM
inhibits the estrogen mediated increase in thyroid cell migration,
adhesion and invasion which was supported by ER-a downreg-
ulation studies. Lastly, we have identified a mechanism behind this
estrogen induced migration, adhesion and invasion in thyroid cells
as induction and activation of essential proteolytic enzymes,
mainly MMP-2 and MMP-9. Taken together, our observations
provide for the first time, direct evidence for the estrogen/ER
mediated regulation of MMP secretion and activity in thyroid
cancer cells. Overall, these findings open a new avenue and
clinical utility for DIM as the prototypical anti-estrogen that can
be used for therapeutic and preventive purposes of thyroid
proliferative diseases by not only suppressing the proliferation of
thyroid cancer cells but also by inhibiting metastasis associated
events.
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